	US 12,011,508 B2
	Methods and devices for reducing vascular smooth muscle cell proliferation
Tammy Renee Dugas, Baton Rouge, LA (US); Cristina Sabliov, Baton Rouge, LA (US); and Carlos Astete, Baton Rouge, LA (US)
Assigned to Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA (US)
Appl. No. 16/965,078
Filed by Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA (US)
PCT Filed Feb. 1, 2019, PCT No. PCT/US2019/016302 § 371(c)(1), (2) Date Jul. 27, 2020, PCT Pub. No. WO2019/152811, PCT Pub. Date Aug. 8, 2019.
Claims priority of provisional application 62/625,026, filed on Feb. 1, 2018.
Prior Publication US 2021/0106728 A1, Apr. 15, 2021
Int. Cl. A61K 9/51 (2006.01); A61K 31/05 (2006.01); A61K 31/366 (2006.01); A61L 29/08 (2006.01); A61L 29/16 (2006.01); A61M 25/10 (2013.01); C08F 220/34 (2006.01)

CPC A61K 9/5153 (2013.01) [A61K 9/5138 (2013.01); A61K 31/05 (2013.01); A61K 31/366 (2013.01); A61L 29/085 (2013.01); A61L 29/16 (2013.01); A61M 25/10 (2013.01); C08F 220/34 (2013.01); A61L 2300/216 (2013.01); A61L 2400/12 (2013.01); A61M 2025/105 (2013.01)]

18 Claims

1. A polymeric nanoparticle composition comprising a first polymer, a second polymer, and a first therapeutic agent;

wherein the first polymer is an acrylate polymer comprising one or more positively charged moieties per polymer chain;

wherein the second polymer is selected from the group consisting of poly(lactide), poly(glycolide), poly(lactide-co-glycolide), poly(caprolactone), poly(lactide-co-caprolactone), poly(glycolide-co-caprolactone), and poly(D, L-lactide-co-glycolide-co-ε-caprolactone); and

wherein the first therapeutic agent is triacetyl resveratrol.

11. A drug coated balloon catheter, comprising:

an expandable balloon having an outer surface;

a nanoparticle coating on the outer surface of the expandable balloon, wherein the nanoparticle coating comprises a first polymer, a second polymer, and a first therapeutic agent;

where the first polymer is an acrylate polymer comprising one or more positively charged moieties per polymer chain;

where the second polymer is selected from the group consisting of poly(lactide), poly(glycolide), poly(lactide-co-glycolide), poly(caprolactone), poly(lactide-co-caprolactone), poly(glycolide-co-caprolactone), and poly(D,L-lactide-co-glycolide-co-ε-caprolactone);

where the first therapeutic agent is triacetyl resveratrol; and

wherein a concentration of the first therapeutic agent on at least a portion of the outer surface of the expandable balloon ranges from about 1 to about 5 μg/mm².